- Advertise
- OLE Scientific Interchange Workshops
- About OncLive
- Editorial Board
- CureToday.com
- TargetedOnc.com
- CancerNetwork.com
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2021 MJH Life Sciences™ and OncLive. All rights reserved.
Vanderbilt-Ingram Cancer Center | Strategic Alliance Partners
Latest from Vanderbilt-Ingram Cancer Center
Lurbinectedin Makes a Splash in Second-Line SCLC
April 05, 2021
Article
Wade T. Iams, MD, discusses the efficacy and safety of lurbinectedin in patients with small cell lung cancer, the impact of its approval on the paradigm, and remaining questions regarding its use.
Dr. Eng on the Rising Incidence of Early-Onset CRC
April 01, 2021
Video
Cathy Eng, MD, FACP, FASCO, discusses the rising incidence of early-onset colorectal cancer.
Dr. Johnson on the Risks and Benefits Associated with Anti–PD-1 Therapy in Melanoma
March 31, 2021
Video
Douglas B. Johnson, MD, discusses the risks and benefits associated with anti–PD-1 therapy in patients with stage III resected melanoma.
Dr. del Rio on the Reactogenicity of the COVID-19 Vaccines
March 24, 2021
Video
Carlos del Rio, MD, discusses the reactogenicity of the COVID-19 vaccines.
Dr. Eng Discusses the Ongoing FRESCO-2 Trial in mCRC
March 23, 2021
Video
Cathy Eng, MD, FACP, FASCO, discusses the ongoing phase 3 FRESCO-2 trial in metastatic colorectal cancer.
Dr. Eng on the Potential of Trastuzumab Deruxtecan in HER2+ mCRC
March 16, 2021
Video
Cathy Eng, MD, FACP, FASCO, discusses the potential of fam-trastuzumab deruxtecan-nxki in patients with HER2-positive metastatic colorectal cancer.